• No results found

Discovery of dormancy associated antigens of Mycobacterium tuberculosis : novel targets for the development of post-exposure or therapeutic tuberculosis vaccines

N/A
N/A
Protected

Academic year: 2021

Share "Discovery of dormancy associated antigens of Mycobacterium tuberculosis : novel targets for the development of post-exposure or therapeutic tuberculosis vaccines"

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

development of post-exposure or therapeutic tuberculosis vaccines

Lin, M.Y.

Citation

Lin, M. Y. (2009, December 15). Discovery of dormancy associated antigens of Mycobacterium tuberculosis : novel targets for the development of post- exposure or therapeutic tuberculosis vaccines. Retrieved from

https://hdl.handle.net/1887/14507

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/14507

Note: To cite this publication please use the final published version (if applicable).

(2)







Discoveryofdormancyassociatedantigens

of Mycobacteriumtuberculosis:



 ‘˜‡Ž–ƒ”‰‡–•ˆ‘”–Š‡†‡˜‡Ž‘’‡–‘ˆ

’‘•–Ǧ‡š’‘•—”‡‘”–Š‡”ƒ’‡—–‹…

–—„‡”…—Ž‘•‹•˜ƒ……‹‡•

 

 

 

 

 

 

 

 

 

 

MayYoungLin

(3)
(4)



 

Discoveryofdormancyassociatedantigens

of Mycobacteriumtuberculosis:



 ‘˜‡Ž–ƒ”‰‡–•ˆ‘”–Š‡†‡˜‡Ž‘’‡–‘ˆ

’‘•–Ǧ‡š’‘•—”‡‘”–Š‡”ƒ’‡—–‹…

–—„‡”…—Ž‘•‹•˜ƒ……‹‡•

 



Proefschrift

 

–‡”˜‡””‹Œ‰‹‰˜ƒ

†‡‰”ƒƒ†˜ƒ‘…–‘”ƒƒ†‡‹˜‡”•‹–‡‹–‡‹†‡ǡ

‘’‰‡œƒ‰˜ƒ‡…–‘”ƒ‰‹ˆ‹…—•’”‘ˆǤ”ǤǤ Ǥ˜ƒ†‡” ‡‹Œ†‡ǡ

˜‘Ž‰‡•„‡•Ž—‹–˜ƒŠ‡–‘ŽŽ‡‰‡˜‘‘””‘‘–‹‡•

–‡˜‡”†‡†‹‰‡‘’†‹•†ƒ‰ͳͷ†‡…‡„‡”ʹͲͲͻ

Ž‘‡ͳ͵ǣͶͷ——”



 

 

†‘‘” 





MinYongLin

‰‡„‘”‡–‡”‘‹‰‡‹ͳͻ͹ͺ

 

(5)

Promotor:

”‘ˆǤ”ǤǤ ǤǤ––‡Š‘ˆˆ



Copromotor: 

”ǤǤǤŽ‡‹(RijksinstituutvoorVolksgezondheidenMilieu,Bilthoven)



Overigeleden: 

”‘ˆǤ”ǤǤǤ ‹‡•–”ƒ

™Ǥ”ǤǤ —›‰‡(WetenschappelijkInstituutVolksgezondheid,Brussel)

”‘ˆǤ”ǤǤ ǤǤ‡Ž‹‡ˆ

”‘ˆǤ”Ǥ ǤǤǤ˜ƒ—––‡(UniversiteitUtrechtȌ















̹ʹͲͲͻǡǤǤ‹ǡ‡‹†‡ǡŠ‡‡–Š‡”Žƒ†•Ǥ

ǣͻ͹ͺǦͻͲǦͻͲʹͶ͹͸͸Ǧ͵

”‹–‡†„›ǣ‹Ž†‡’”‹–”—‡”‹Œ‡Ȃ•…Š‡†‡ǡŠ‡‡–Š‡”Žƒ†•

‹‡–•—‹–†‡œ‡—‹–‰ƒ˜‡ƒ‰˜‡”˜‡‡Ž˜‘—†‹‰†‡Ȁ‘ˆ‘’‡„ƒƒ”‰‡ƒƒ–™‘”†‡œ‘†‡”

˜‘‘”ƒˆ‰ƒƒ†‡•…Š”‹ˆ–‡Ž‹Œ‡–‘‡•–‡‹‰˜ƒ†‡ƒ—–‡—”Ǥ‘’ƒ”–‘ˆ–Š‹•–Š‡•‹•ƒ›„‡

”‡’”‘†—…‡†‹ƒ›ˆ‘”™‹–Š‘—–™”‹––‡’‡”‹••‹‘ˆ”‘–Š‡ƒ—–Š‘”Ǥ

‘˜‡”ǣMycobacteriumtuberculosis

‘˜‡”‡•‹‰ǣ”ƒ†‡ ƒ‰‡”

ƒ›‘—–ǣƒ›‘—‰‹

Š‡•–—†‹‡•†‡•…”‹„‡†‹–Š‹•–Š‡•‹•™‡”‡’‡”ˆ‘”‡†ƒ––Š‡‡’ƒ”–‡–‘ˆ ˆ‡…–‹‘—•

‹•‡ƒ•‡• ƒ† ƒ– –Š‡ ‡’ƒ”–‡– ‘ˆ —‘Š‡ƒ–‘Ž‘‰› Ƭ Ž‘‘† ”ƒ•ˆ—•‹‘ ƒ– –Š‡

‡‹†‡ ‹˜‡”•‹–› ‡†‹…ƒŽ ‡–”‡ ƒ† ™ƒ• ˆ—†‡† „› –Š‡ ‘—†ƒ–‹‘ ‹…”‘„‹‘Ž‘‰›

‡‹†‡ ȋ–‹…Š–‹‰ ‹…”‘„‹‘Ž‘‰‹‡ ‡‹†‡Ȍǡ  Šƒ”ƒ…‡—–‹…ƒŽ• ǤǤǡ ƒ† –Š‡ Ǧ ͸

’”‘Œ‡…–ǦǤ

•‡†„›’‡”‹••‹‘ǢŠƒ’–‡”ͳƬͺǦ̹ʹͲͲͺ‡–Šƒ…‹‡…‡—„Ž‹•Š‡”•–†Ǥƒ†̹

ʹͲͲͺ„›ƒŽ–‡”†‡”—›–‡”x‡”Ž‹x‡™‘”

—„Ž‹…ƒ–‹‘‘ˆ–Š‹•–Š‡•‹•™ƒ•ˆ‹ƒ…‹ƒŽŽ›•—’’‘”–‡†„›—„‡”…—Ž‘•‹• ‘—†ƒ–‹‘ǡ

Ǧ›‡…Š‹‘•…‹‡…‡•ǡ‹‘•…‹‡…‡•ƒ†Ž‡ƒ‹”‡…Š‹‡ǤǤ



(6)



 

 

     

 

 

 

        

 

 

 

 

 

 





















Voordewetenschap

       

(7)













































 

(8)



CONTENTS



Šƒ’–‡”ǣ

ͳ ‡‡”ƒŽ‹–”‘†—…–‹‘       ͳͳ

 

 EndocrMetabImmuneDisordDrugTargets.2008Mar;8(1):1529

 BiolChem.2008May;389(5):497511.

ʹ —ƒǦ…‡ŽŽ”‡•’‘•‡•–‘ʹͷ‘˜‡Žƒ–‹‰‡•‡…‘†‡†„›‰‡‡•‘ˆ–Š‡Ͷͳ

 †‘”ƒ…›”‡‰—Ž‘‘ˆMycobacteriumtuberculosis

 

 MicrobesInfect.2006Jul;8(8):20522060.

͵ †‡–‹ˆ‹…ƒ–‹‘‘ˆͶΪƒ†ͺΪ…‡ŽŽ”‡•’‘•‡•–‘Mycobacteriumͷ͹

 tuberculosis‘•”‡‰—Ž‘‡…‘†‡††‘”ƒ…›ƒ–‹‰‡•ƒ†ƒ’’‹‰

 ‘ˆ …Žƒ•• ƒ† ”‡•–”‹…–‡†’‡’–‹†‡Ǧ‡’‹–‘’‡•



 Manuscriptinpreparation



Ͷ ƒ…‘ˆ‹—‡”‡•’‘•‡•–‘Mycobacteriumtuberculosis‘•”‡‰—Ž‘ͺͷ

 ’”‘–‡‹•ˆ‘ŽŽ‘™‹‰Mycobacteriumbovis˜ƒ……‹ƒ–‹‘



 InfectImmun.2007Jul;75(7):35233530.



ͷ Ǧ…‡ŽŽ”‡…‘‰‹–‹‘‘ˆ–Š‡ •’’”‘–‡‹‘ˆMycobacteriumtuberculosisͳͲ͵

 …‘””‡Žƒ–‡•™‹–ŠŽƒ–‡–M.tuberculosis‹ˆ‡…–‹‘„—–‘–™‹–Š

 M.bovis˜ƒ……‹ƒ–‹‘

 InfectImmun.2007Jun;75(6):29142921



͸ ”‘••Ǧ”‡ƒ…–‹˜‡‹—‹–›–‘Mycobacteriumtuberculosis‘•ͳͳͻ

 ”‡‰—Ž‘Ǧ‡…‘†‡†ƒ–‹‰‡•‹‹†‹˜‹†—ƒŽ•‹ˆ‡…–‡†™‹–Š‡˜‹”‘‡–ƒŽǡ

 ‘Ǧ–—„‡”…—Ž‘—•›…‘„ƒ…–‡”‹ƒ

 

 InfectImmun.2009Nov:77(11):50715079



͹ —Ž‘ƒ”›†‡Ž‹˜‡”›‘ˆ‡…‘†‹‰MycobacteriumtuberculosisͳͶ͵

 Žƒ–‡…›ƒ–‹‰‡˜ͳ͹͵͵…ƒ••‘…‹ƒ–‡†–‘Ǧ ƒ‘’ƒ”–‹…Ž‡•

 ‡Šƒ…‡•…‡ŽŽ”‡•’‘•‡•‹ƒ’”‹‡Ȁ’”‘–‡‹„‘‘•–˜ƒ……‹ƒ–‹‘

 ”‡‰‹‡‹‹…‡



 Vaccine.2009Jun19;27(30):40104017

ͺ —ƒ”›ƒ†‡‡”ƒŽ‹•…—••‹‘    ͳ͸ͳ

 ‡†‡”Žƒ†•‡ƒ‡˜ƒ––‹‰     ͳ͹ͷ

 …‘™Ž‡†‰‡‡–•      ͳ͹ͻ

 —””‹…—Ž—‹–ƒ‡      ͳͺͳ

 ‹•–‘ˆ—„Ž‹…ƒ–‹‘•      ͳͺ͵

 ‹•–‘ˆ„„”‡˜‹ƒ–‹‘•      ͳͺͷ



(9)





































 

Referenties

GERELATEERDE DOCUMENTEN

tuberculosis  in  infected  murine  lung  tissue.  Five  dormancy  genes  were  selected 

Discovery of dormancy associated antigens of Mycobacterium tuberculosis : novel targets for the development of post-exposure or therapeutic tuberculosis vaccines.. Retrieved

Discovery of dormancy associated antigens of Mycobacterium tuberculosis : novel targets for the development of post-exposure or therapeutic tuberculosis vaccines Lin, M.Y...

Discovery of dormancy associated antigens of Mycobacterium tuberculosis : novel targets for the development of post-exposure or therapeutic tuberculosis vaccines Lin, M.Y...

ͳǦʹͲ ͳͳǦ͵Ͳ ʹͳǦͶͲ ͵ͳǦͷͲ ͶͳǦ͸Ͳ ͷͳǦ͹Ͳ ͸ͳǦͺͲ ͹ͳǦͻͲ ͺͳǦͳͲͲ ͻͳǦͳͳͲ ͳͲͳǦͳʹͲ ͳͳͳǦͳ͵Ͳ ͳʹͳǦͳͶͲ ͳ͵ͳǦͳͷͲ ͳͶͳǦͳ͸Ͳ ͳͷͳǦͳ͹Ͳ ͳ͸ͳǦͳͺͲ ͳ͹ͳǦͳͻͲ ͳͺͳǦʹͲͲ ͳͻͳǦʹͳͲ

Discovery of dormancy associated antigens of Mycobacterium tuberculosis : novel targets for the development of post-exposure or therapeutic tuberculosis vaccines Lin, M.Y...

Considering the lack of efficient MVA85A vaccination mediated boosting against clinical tuberculosis in infants vaccinated with BCG 41 , this character of

Mycobacterial – whole cell or extract Mycobacterial – live.